Esophageal Cancer Market Size in the 7MM was ~USD 1,000 Million in 2023, it is expected to grow by 2034, estimates DelveInsight

In the 7 major markets (7MM), the esophageal cancer market was estimated at approximately USD 1,000 million in 2023 and is expected to grow at a notable compound annual growth rate (CAGR) over the forecast period from 2020 to 2034. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Esophageal Cancer landscape.

Across the EU4 and the UK, the UK captured the largest portion of the esophageal cancer market, accounting for roughly 36% of the total, with Germany holding the second-largest share. Among the seven major markets, Japan reported the highest number of newly diagnosed esophageal cancer cases at approximately 26,000 in 2023, followed by the United States.

In 2023, age-specific data indicated that individuals aged 65 and above had the highest number of esophageal cancer cases in the United States, whereas those under 45 accounted for the fewest cases. Additionally, males represented 80% of cases, compared to 20% in females.

In 2023 in the United States, histology-specific data showed approximately 12,500 new cases of non-squamous esophageal cancer and around 7,300 new cases of squamous esophageal cancer. Within the EU4 and the UK, the UK reported the highest number of newly diagnosed esophageal cancer cases.

In 2023, TP53 was the most frequently observed mutation, present in about 80% of all diagnosed incident esophageal cancer cases across the seven major markets (7MM).

DelveInsight’s report “Esophageal Cancer Market Insights, Epidemiology, and Market Forecast-2034” provides a comprehensive analysis of the Esophageal Cancer landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Esophageal Cancer market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Esophageal Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Esophageal Cancer Market Forecast

Some of the key facts of the Esophageal Cancer Market Report:

• Key Esophageal Cancer Companies: Eli Lilly and Company, Bayer, Zymeworks, Jazz Pharmaceuticals, Amgen, Jazz Pharmaceuticals, Zymeworks, BeiGene, AstraZeneca, Symphogen, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences, and others
• Key Esophageal Cancer Therapies: CYRAMZA (ramucirumab), VITRAKVI (larotrectinib), Zanidatamab, Bemarituzumab, Zanidatamab, Tislelizumab, XB002, LGK974, Abemaciclib, ladiratuzumab vedotin, ATRC-101, SGN-PDL1V, RO7247669, THOR-707, Letetresgene Autoleucel, TNO155, Anlotinib Hydrochloride, Larotinib, SCT-I10A, Serplulimab, CS1001, Camrelizumab, Durvalumab, Sym021, Spartalizumab, Sym022, Sym023, Regorafenib, S095033, INCB099318, RO7121661, KF-0210, SCT200, Ramucirumab, Cabozantinib, JAB-3068, Onivyde, JAB-3312, SGN-B6A, RAPA-201,Ociperlimab, SI B001,Apatinib, and others
• The Esophageal Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Esophageal Cancer pipeline products will significantly revolutionize the Esophageal Cancer market dynamics.

Esophageal Cancer Overview

Esophageal Cancer is a malignant tumor that develops in the esophagus, the tube connecting the throat to the stomach. It primarily occurs in two forms: squamous cell carcinoma, which arises from the lining cells of the esophagus, and adenocarcinoma, which develops from glandular cells, often in the lower esophagus. Risk factors include smoking, alcohol consumption, gastroesophageal reflux disease (GERD), Barrett’s esophagus, and obesity. Symptoms may include difficulty swallowing, chest pain, weight loss, and persistent cough. Early detection is critical, as advanced stages are often aggressive and associated with poor prognosis.

Get a Free sample for the Esophageal Cancer Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/esophageal-cancer-market 

Key Trends in Esophageal Cancer Therapeutics Market:

• Growing adoption of immunotherapy and targeted therapies: Immune checkpoint inhibitors (e.g., pembrolizumab/Keytruda, tislelizumab-based regimens) and molecularly targeted drugs are increasingly integrated into standard treatment plans, improving survival outcomes versus conventional chemotherapy.
• Shift toward patient-friendly formulations and precision medicine: Development of novel delivery formats (e.g., subcutaneous immunotherapies) and personalized treatments based on genetic/molecular profiling are enhancing treatment convenience and tailoring therapies to individual tumor biology.
• Rising incidence and expanded patient access: The global increase in esophageal cancer cases, especially in high-burden regions like Asia Pacific, coupled with favorable regulatory approvals and reimbursement policies, is driving demand for advanced therapeutics.
• Focus on combination and multimodal strategies: Clinical research is emphasizing combination approaches (e.g., immunotherapy with chemotherapy or targeted agents) to enhance efficacy and overcome resistance, reflecting a broader trend toward integrated treatment regimens.
• Enhanced diagnostics and early detection fueling therapy use: Improvements in early detection (endoscopic screening, biomarker assays) and companion diagnostics are enabling earlier intervention and better selection of therapeutic options, supporting more effective care pathways. 

Esophageal Cancer Epidemiology

The Esophageal Cancer epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Esophageal Cancer Epidemiology Segmentation:

The Esophageal Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Esophageal Cancer
• Prevalent Cases of Esophageal Cancer by severity
• Gender-specific Prevalence of Esophageal Cancer
• Diagnosed Cases of Episodic and Chronic Esophageal Cancer

Download the report to understand which factors are driving Esophageal Cancer epidemiology trends @ Esophageal Cancer Epidemiology Forecast

Recent Development In The Esophageal Cancer Treatment Landscape:

 

Esophageal Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Esophageal Cancer market or expected to get launched during the study period. The analysis covers Esophageal Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Esophageal Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Esophageal Cancer Therapies and Key Companies

• CYRAMZA (ramucirumab): Eli Lilly and Company
• VITRAKVI (larotrectinib): Bayer
• Zanidatamab: Zymeworks/Jazz Pharmaceuticals
• Bemarituzumab: Amgen
• Zanidatamab: Jazz Pharmaceuticals/Zymeworks
• Tislelizumab: BeiGene
• Durvalumab: Celgene/MedImmune
• Tucatinib: Seagen
• M1231: Merck KGaA
• APX 005M: Apexigen
• Erdafitinib: Janssen Research & Development, LLC
• Margetuximab: MacroGenics
• AN-0025: Adlai Nortye

Discover more about therapies set to grab major Esophageal Cancer market share @ Esophageal Cancer Treatment Landscape

Esophageal Cancer Market Drivers

• Rising incidence of esophageal cancer globally: Increasing lifestyle risk factors (smoking, obesity, GERD) and demographic shifts contribute to higher diagnosis rates, expanding demand for effective treatments.
• Advancements in therapeutic options: Novel immunotherapies, targeted agents, and antibody engineering are improving survival outcomes and broadening treatment choices, fueling physician adoption.
• Greater awareness and screening initiatives: Public health campaigns and screening programs support earlier detection and referral, enhancing treatment uptake and improving prognosis.
• Investment in R&D and clinical innovation: Increased research funding and clinical development of personalized and combination therapies drive innovation and expand potential market offerings.
• Improved healthcare infrastructure and access in key regions: Expansion of oncology services in emerging markets and supportive reimbursement policies help broaden access to advanced treatments.

Esophageal Cancer Market Strengths

• High treatment costs and affordability issues: Expensive therapies, particularly immunotherapies and biologics, remain unaffordable for many patients, limiting adoption in low- and middle-income regions.
• Limited early diagnosis and late-stage detection: Absence of widespread early screening leads to diagnoses at advanced stages, reducing treatment effectiveness and survival outcomes.
• Varying access to specialized care: Disparities in healthcare infrastructure and oncology expertise constrain treatment availability in underserved areas.
• Clinical and regulatory challenges: Stringent regulatory processes, high clinical trial failure rates, and complex tumor biology slow new drug approvals and market entry.
• Treatment limitations and side effects: Limited efficacy of some current therapies and therapy-related adverse effects can affect patient adherence and long-term outcomes.

Scope of the Esophageal Cancer Market Report

• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Esophageal Cancer Companies: Eli Lilly and Company, Bayer, Zymeworks, Jazz Pharmaceuticals, Amgen, AstraZeneca, Symphogen, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences, and others
• Key Esophageal Cancer Therapies: CYRAMZA (ramucirumab), VITRAKVI (larotrectinib), Zanidatamab, Bemarituzumab, Zanidatamab, Tislelizumab, XB002, LGK974, Abemaciclib, ladiratuzumab vedotin, ATRC-101, SGN-PDL1V, RO7247669, THOR-707, Letetresgene Autoleucel, TNO155, Anlotinib Hydrochloride, Larotinib, SCT-I10A, Serplulimab, CS1001, Camrelizumab, Durvalumab, Sym021, Spartalizumab, Sym022, Sym023, Regorafenib, S095033, INCB099318, RO7121661, KF-0210, SCT200, Ramucirumab, Cabozantinib, JAB-3068, Onivyde, JAB-3312, SGN-B6A, RAPA-201,Ociperlimab, SI B001,Apatinib, and others
• Esophageal Cancer Therapeutic Assessment: Esophageal Cancer current marketed and Esophageal Cancer emerging therapies
• Esophageal Cancer Market Dynamics: Esophageal Cancer market drivers and Esophageal Cancer market barriers 
• Esophageal Cancer Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Esophageal Cancer Unmet Needs, KOL’s views, Analyst’s views, Esophageal Cancer Market Access and Reimbursement 

To know more about Esophageal Cancer companies working in the treatment market, visit @ Esophageal Cancer Clinical Trials and Therapeutic Assessment

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.